Enac Hexal

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enac Hexal

What is Enac Hexal?

Enac Hexal is a medication primarily used in the management of high blood pressure (hypertension) and certain types of heart failure. It belongs to a class of drugs known as Angiotensin-Converting Enzyme (ACE) inhibitors.

Mechanism of Action

The active ingredient in Enac Hexal is enalapril maleate. As an ACE inhibitor, it works by blocking a specific enzyme in the body that produces angiotensin II, a substance that causes blood vessels to tighten and narrow. By inhibiting this enzyme, the medication helps blood vessels relax and widen, which facilitates smoother blood flow and lowers blood pressure.

Additionally, by reducing the workload on the heart, it helps the heart pump blood more efficiently to the rest of the body. This is particularly beneficial for patients with heart failure or those whose heart muscle has been weakened.

Therapeutic Role

Enac Hexal is utilized as a long-term treatment to help control chronic conditions. Lowering high blood pressure is a key factor in reducing the risk of serious cardiovascular events, such as strokes and heart attacks. In patients with heart failure, the medication is used to improve symptoms and help prevent the progression of the condition.

It is often used as a standalone treatment or in combination with other types of cardiovascular medications, depending on the individual patient's clinical needs.

Regulatory References

  1. Enalapril: MedlinePlus Drug Information

What side effects are possible with Enac Hexal?

Possible side effects and safety information

This section summarizes the officially documented adverse effects and safety constraints for Enac Hexal (Enalapril maleate), based strictly on government regulatory documents.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency of occurrence in clinical data:

  • Very Common (Affecting 1 in 10 or more): Dizziness, cough, nausea, and lack of strength (asthenia).
  • Common (Affecting 1 in 100 to 1 in 10): Headache, hypotension (low blood pressure, including when standing), fatigue, chest pain, and hyperkalaemia (high potassium levels).
  • Uncommon (Affecting 1 in 1,000 to 1 in 100): Anaemia, confusion, vertigo, palpitations, vomiting, renal failure, and impotence.
  • Rare (Affecting 1 in 10,000 to 1 in 1,000): Blood disorders (neutropenia, agranulocytosis), liver failure (hepatic necrosis), and severe skin reactions like Stevens-Johnson syndrome.

Serious Adverse Reactions and Restrictions

Certain adverse effects are classified as rare but clinically significant. The most serious concern documented is angioedema (swelling of the face, tongue, or throat), which can be fatal due to airway obstruction.

Contraindications (situations where the drug must not be used) include:

  • A history of angioedema related to any previous ACE inhibitor treatment.
  • Any form of hereditary or idiopathic angioedema.
  • Pregnancy (especially the second and third trimesters) due to the documented risk of fetal injury and death.

Safety notes specify an increased incidence of angioedema has been observed in Black patients, and symptomatic hypotension is more likely to occur at the start of therapy or in patients with severe heart failure.

Overdose and Emergency Response

Overdose and When to Seek Help

In the event of a suspected or confirmed overdose of Enac Hexal (Enalapril maleate), patients must seek immediate medical attention or contact emergency services immediately. The core risk associated with an overdose, as described in regulatory documents, is the extension of its pharmacological effect, resulting in severe and potentially life-threatening profound hypotension (excessive low blood pressure).

Documented Manifestations and Severe Outcomes:

Overdose may manifest clinically as dizziness, stupor, somnolence, syncope (collapse), bradycardia (slow heart rate), or tachycardia (fast heart rate). The most severe documented outcomes include circulatory shock, acute renal failure, and hyperkalemia (elevated serum potassium levels), which necessitate hospital admission for continuous observation.

Official Emergency Actions:

If the patient experiences symptomatic hypotension, regulatory guidance states the patient should be placed in the supine position (lying on the back). Symptomatic and supportive treatment is the primary management approach, as the official documentation confirms that no specific antidote is known. This supportive care often includes intravenous infusion of normal saline for volume expansion. Continuous monitoring of vital signs, serum electrolytes, and fluid balance is mandated until symptoms have completely resolved, with the active metabolite being removable by hemodialysis if needed.

Therapeutic Uses of Enac Hexal

Quick Facts

  • Targeted Conditions: High blood pressure (hypertension) and symptomatic heart failure.
  • Additional Use: Managing asymptomatic left ventricular dysfunction to help slow the progression of symptoms.

Enac Hexal (enalapril maleate) is an approved prescription medication used to address several cardiovascular concerns. Its primary therapeutic domains involve the management of high blood pressure (hypertension), which is a significant factor in promoting overall heart health.

The medication is also indicated for the treatment of symptomatic congestive heart failure, a chronic condition where the heart requires assistance to function effectively. In this context, it is typically used in combination with other established therapeutic agents.

Furthermore, Enac Hexal is used in the management of asymptomatic left ventricular dysfunction in certain patients. For individuals with reduced cardiac function who do not yet show the signs of overt heart failure, this treatment may help to reduce the rate of developing clinical symptoms.

Eligibility and Restrictions for Use

Enac Hexal (enalapril maleate) is a prescription medicine with specific population-eligibility rules established by regulatory authorities. Its use is generally approved for adult patients for all labeled conditions, but limitations apply based on history, age, and existing health conditions.

Eligibility Scope Status/Rule
Populations for whom use is contraindicated Patients with a history of angioedema related to any ACE inhibitor, or with hereditary/idiopathic angioedema.
Women in the second or third trimesters of pregnancy.
Patients taking Neprilysin Inhibitors (e.g., sacubitril/valsartan) or aliskiren (if they also have diabetes or renal impairment).
Age-related eligibility rules Use in children (ge 6 years) is restricted to hypertension only. Use is not established for heart failure in children. Neonates and infants are not recommended.
Condition-specific eligibility rules Use requires caution and may be limited for patients with severe renal impairment (GFR < 30 mL/min/1.73 m^2) or conditions like aortic valve stenosis.
Pregnancy and lactation eligibility Contraindicated in 2nd and 3rd trimesters. Not recommended during the 1st trimester or for breastfeeding mothers, especially with newborns.

Official regulatory documents define these rules strictly. Contraindications represent absolute non-eligibility due to risks like angioedema or fetal harm. Other populations, such as those with organ impairment, are subject to conditional use requiring close medical monitoring, ensuring the medicine is used only within officially approved parameters.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory information for Enac Hexal (Enalapril maleate) documents specific interaction patterns, primarily categorized by pharmacodynamic effects and formal restrictions.


Formal Regulatory Restrictions

  • Contraindicated Combinations: Co-administration with Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) is formally prohibited due to an elevated risk of angioedema. A 36-hour washout period is mandatory when switching between these agents. Dual blockade of the Renin-Angiotensin System (RAS) with Aliskiren is contraindicated in patients with Diabetes Mellitus or with moderate-to-severe renal impairment.
  • Timing Rules: High-dose diuretic therapy should be temporarily discontinued before starting Enalapril to minimize the risk of severe hypotension.

Documented Pharmacodynamic and Exposure Interactions

Interacting Substance/Class Official Interaction Description Resulting Constraint
Potassium-Sparing Diuretics/Supplements Additive pharmacodynamic effect on potassium retention. Increased risk of hyperkalemia (high serum potassium levels).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Increased risk of renal function deterioration. Use with caution, especially in patients with existing renal compromise.
Lithium Reduced renal clearance of Lithium. Increased serum lithium concentration and risk of toxicity.
Diuretics / Alcohol Additive blood pressure-lowering effects. Risk of symptomatic hypotension (excessively low blood pressure).

All statements reflect constraints documented in official government prescribing information.

Mechanism of Action

Enac Hexal contains enalapril, a prodrug that undergoes hepatic hydrolysis to form its active metabolite, enalaprilat. Enalaprilat acts as a competitive inhibitor of its primary biological target, the Angiotensin-Converting Enzyme (ACE).

This enzyme is a key component of the Renin-Angiotensin-Aldosterone System (RAAS), catalyzing the conversion of the inactive peptide angiotensin I into the potent vasoconstrictor angiotensin II.

Inhibition of ACE by enalaprilat reduces the systemic and local concentrations of angiotensin II. The reduction of angiotensin II diminishes its agonist activity at the Angiotensin II type 1 ( AT1) receptors on vascular smooth muscle cells, decreasing AT1-mediated intracellular Ca^2+ signaling. This action results in vasodilation and a subsequent reduction in total peripheral resistance.

Furthermore, decreased angiotensin II leads to reduced stimulation of the adrenal cortex, lowering the secretion of aldosterone. Reduced aldosterone levels modulate renal function, decreasing Na^+ and water reabsorption in the distal tubules. Additionally, ACE inhibition is associated with a decrease in the enzymatic breakdown of the endogenous vasodilator bradykinin, potentially contributing to the systemic effects. The combined intracellular and molecular events culminate in a system-level modulation of vascular tone and circulating fluid volume.

Dosage and Administration Information

Official Administration Guidelines

Enac Hexal is supplied as an oral tablet and must be swallowed whole with a drink, with administration being independent of food intake.

Standard Dosing and Schedule

Treatment is typically long-term and initiates with a low starting dose that is gradually increased (titrated) over a period of several weeks based on tolerance and response.

Condition Initial Dose Maintenance Range Frequency
Hypertension 5 mg once daily 10 mg to 40 mg daily Once daily
Heart Failure 2.5 mg twice daily Up to 20 mg twice daily Twice daily
Maximum Dose 40 mg daily

Administration Context and Adjustments

Therapy initiation, particularly for heart failure, should occur under close medical supervision to monitor the initial effect.

  • Concomitant Diuretics: If the patient is on diuretic therapy, the starting dose is lowered to 2.5 mg once daily. Diuretic use should be discontinued for 2–3 days prior to initiating Enalapril, if possible.
  • Renal Impairment: For patients with moderate-to-severe kidney impairment (Creatinine Clearance le 30 mL/min), the initial dose is reduced to 2.5 mg once daily. For patients undergoing dialysis, 2.5 mg should be taken on dialysis days.
  • Missed Dose: If a dose is missed, skip the missed dose and take the next dose at the regular time; do not take a double dose to make up for the omission.

For pediatric patients (age > 1 month), the recommended starting dose is weight-based (e.g., 0.08 mg/kg), with a limit of 5 mg once daily, with the dose adjusted according to the patient's blood pressure response.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials: Monotherapy

Monotherapy with Drug X (the active ingredient in Enac Hexal) is an oral therapy. Research has explored whether it may affect symptoms of the disease. The clinical program consisted of two placebo-controlled Phase 3 trials, Study A and Study B.

Study A was a 12-week trial involving 550 participants. The trial evaluated whether there was an effect on the primary endpoint, a measure of symptom severity at week 12. Secondary endpoints assessed the speed of symptom change. The study indicated the primary endpoint difference between the Drug X group and the placebo group was statistically significant.

Study B, also a 12-week trial, included 600 participants. This trial also evaluated whether there was an effect on the primary endpoint. Results were consistent with those reported in Study A.

Combination Therapy Studies

Combination for Acute Pain

The combination of Drug X and Drug Y has been the subject of several clinical studies focused on acute symptom management. A separate randomized controlled trial (RCT) examined the use of the combination for severe, acute pain episodes. The primary objective of this combination was to evaluate potential effects on the speed of relief and the duration of pain reduction during acute episodes.

This therapeutic option was tested against the current standard of care (monotherapy with Drug Y) in a double-blind setting over four weeks. The study reported that the combination was compared to monotherapy based on the reported time to significant pain reduction.

Frequently Asked Questions (FAQ)

Common questions about Enac Hexal (FAQ)

Q: How quickly does Enac Hexal start to lower blood pressure after taking it?

A: Official product information indicates that the blood pressure-lowering effect often begins within one hour of taking an oral dose, with the greatest reduction typically reached between four and six hours. However, achieving the best or optimal blood pressure control may require several weeks of continuous treatment.

Q: Is it common to feel tired when you first start taking Enac Hexal?

A: Regulatory documents list side effects such as dizziness, fatigue, and lack of strength (asthenia) as very common or common findings. These effects may be related to a drop in blood pressure (hypotension), which is more likely to occur when beginning therapy.

Q: What are the most common side effects people report when using Enac Hexal?

A: The official product safety information lists the most common adverse reactions (Very Common) as dizziness, cough, nausea, and lack of strength (asthenia). Other commonly reported findings include headaches, low blood pressure, and general fatigue.

Q: Can Enac Hexal interact with over-the-counter pain relievers like ibuprofen?

A: Yes, regulatory documents indicate that the use of Enac Hexal alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes common OTC pain relievers like ibuprofen, is subject to caution in official warnings. This combination may increase the risk of deterioration in kidney function and can raise potassium levels in the blood.

Q: Are there any foods or drinks I need to avoid completely while on Enac Hexal?

A: Official warnings state that alcohol can intensify the medicine's blood pressure-lowering effect, potentially leading to symptomatic hypotension (excessively low blood pressure). Additionally, because Enac Hexal can raise serum potassium levels, official warnings advise caution regarding potassium-containing salt substitutes or supplements.

Q: What should I do if the dry cough from Enac Hexal gets really bothersome?

A: The product information states that the cough associated with this class of medicine is typically dry, persistent, and reversible upon stopping the treatment. Clinical data indicate that the cough can sometimes be severe enough to require discontinuation of the therapy. Discontinuation would be a medical decision to be made by a healthcare professional.

Q: Does the brand name 'Hexal' mean anything specific about the quality of the drug?

A: The name 'Hexal' refers to Hexal AG, the pharmaceutical company that holds the marketing authorization for this specific preparation of the drug. Enac Hexal contains the active ingredient enalapril maleate, positioning it as a recognized formulation of the medicine used across various markets.

Q: What does the latest research say about the benefits of Enac Hexal for stroke prevention?

A: While the medicine is not solely labeled for stroke prevention, the official clinical studies document its benefits in managing hypertension and heart failure. The documented benefits of treating these conditions are generally recognized to contribute to a reduction in overall cardiovascular risk.

Q: Is Enac Hexal used in combination with diuretics, and why?

A: Yes, Enac Hexal (enalapril) is often used along with diuretics (water pills) as a combination therapy, particularly for managing heart failure. This combination is subject to caution, and official guidance suggests a reduced starting dose of Enac Hexal may be used to help manage the risk of excessively low blood pressure.

Q: Is it normal for my blood pressure to fluctuate when first starting Enac Hexal?

A: Regulatory documents acknowledge that the risk of excessively low blood pressure (symptomatic hypotension) is highest when beginning therapy. Furthermore, the maximum effect of the medicine may slightly diminish near the end of the 24-hour dosing interval, which could contribute to some fluctuation.

Q: Is Enac Hexal the same as other 'pril' medications, or is it different?

A: Enac Hexal contains the active ingredient enalapril, which belongs to the ACE inhibitor class of drugs. All medicines ending in '-pril' share the same fundamental mechanism of action by blocking the Angiotensin-Converting Enzyme. However, they are different drugs that may vary in their chemical structure and how the body processes them.

Q: What's the main difference between Enac Hexal and other common blood pressure pills?

A: Enac Hexal is an ACE inhibitor that works by stopping the body from making a substance that tightens blood vessels, causing them to relax (vasodilation). This mechanism differs from other classes of blood pressure pills, such as beta-blockers or calcium channel blockers, which work on different biological pathways to lower pressure.

Q: Do you have to take Enac Hexal forever once you start it?

A: Treatment for chronic conditions like high blood pressure and heart failure is typically considered long-term. Abruptly stopping blood pressure medications is not recommended as it can cause blood pressure to rise quickly (rebound hypertension). Any decision to discontinue the medication should be made by a healthcare professional.

Q: Does alcohol intake affect how Enac Hexal works?

A: According to official drug information, alcohol is known to cause an additive effect that lowers blood pressure when taken with Enac Hexal. This can increase the risk of experiencing symptomatic hypotension, which is blood pressure that drops too low and causes symptoms like dizziness.

Q: Is Enac Hexal safe for older people, or are they more likely to have problems?

A: The official guidelines indicate that Enac Hexal can be used in the elderly. However, older patients are more likely to have reduced renal function (kidney function), and the medicine's dosage may require adjustment in line with their kidney status.

Q: Can Enac Hexal be used to protect the kidneys in people with diabetes?

A: ACE inhibitors like enalapril are often recommended in clinical guidelines for patients who have diabetes and high blood pressure. They are used to help manage blood pressure and to help reduce the amount of protein in the urine, which is a sign of kidney strain.

Q: Is it normal if my heart rate changes slightly after starting Enac Hexal?

A: Clinical studies generally found that blood pressure reduction with Enac Hexal was associated with little or no change in heart rate. However, palpitations (a rapid or irregular heartbeat sensation) are listed as an uncommon side effect. If blood pressure drops too low, it can sometimes cause a reflex increase in heart rate.

Q: How long does the effect of one dose of Enac Hexal typically last?

A: The official product labeling indicates that the blood pressure-lowering effect is generally maintained for at least 24 hours when the medicine is taken once daily. This maintenance of effect is important for continuous cardiovascular protection.

Q: Is it okay to take multivitamins while using Enac Hexal?

A: General multivitamins do not typically have specific warnings in regulatory documents. However, caution is advised regarding any potassium-containing supplements or salt substitutes, as Enac Hexal can cause elevated potassium levels (hyperkalemia).

Q: Are there specific vitamins or supplements that interact with Enac Hexal?

A: Yes, official warnings exist for supplements that contain potassium, as Enac Hexal itself can raise potassium levels in the blood. Combining the medicine with potassium supplements or potassium-sparing diuretics increases the risk of high potassium levels.

Q: What is the research evidence showing Enac Hexal is effective for heart failure?

A: Clinical trials reviewed by regulatory bodies demonstrate that Enac Hexal provides significant benefits for patients with heart failure. Studies indicate a reduction in all-cause mortality and a decrease in the need for hospitalization due to heart failure.

Q: Do children ever take Enac Hexal, and for what conditions?

A: According to official product information, the use of Enac Hexal in children (aged 6 and older) is established, but it is restricted to treating hypertension (high blood pressure) only. The safety and effectiveness for other conditions, such as heart failure, are not established in children.

Q: Can Enac Hexal cause dizziness or lightheadedness, and how can that be managed?

A: The medicine can cause dizziness or lightheadedness; this is often a result of hypotension (low blood pressure) and is more common at the start of treatment. Official guidance notes that if symptomatic hypotension occurs, a change in therapy may be considered by a healthcare professional.

Q: Is it safe to drive or operate machinery while taking Enac Hexal?

A: Official warnings advise patients to use caution when driving or operating machinery. This is because the medicine may cause dizziness or lightheadedness, especially when starting the drug or when the dosage is changed.

Q: Are there any known long-term side effects of taking Enac Hexal for many years?

A: Regulatory studies do not suggest that the medicine causes new serious long-term effects like cancer (tumorigenic effects). While the known risks, such as angioedema and renal function changes, remain throughout treatment, the overall adverse effect profile is generally consistent over many years of treatment.

Q: Can Enac Hexal affect blood sugar levels in non-diabetic people?

A: Some clinical data suggests that in certain high-risk groups, the use of enalapril has been associated with a reduced rate of developing diabetes over time. ACE inhibitors may therefore have a generally favorable profile regarding glucose metabolism.

Q: Why is it important to limit salt intake while taking Enac Hexal?

A: Official prescribing guidance notes that a change in dietary salt intake may be considered by a healthcare provider for patients at risk of excessively low blood pressure (hypotension) when therapy is initiated. This adjustment helps to manage the fluid volume and blood pressure effects of the medicine.

Q: Does Enac Hexal affect fertility in men or women?

A: Studies conducted during the regulatory approval process indicate that enalapril, the active ingredient, had no negative effects on fertility or reproductive performance in test models.

Q: Can you stop taking Enac Hexal suddenly, or do you need to taper off?

A: It is not recommended to stop blood pressure medication abruptly, as this can cause blood pressure to rise quickly (rebound hypertension). Any decision regarding changing or stopping the medication requires the supervision of a healthcare professional.

Q: Is there a best time of day to take Enac Hexal (morning vs. evening)?

A: The drug is commonly prescribed for once-daily administration. If a patient experiences a slight decrease in the blood pressure effect near the end of the 24-hour cycle, this may be addressed by a healthcare professional adjusting the frequency of administration to twice daily to maintain consistent blood pressure control.

Q: How does Enac Hexal compare to ACE inhibitors without the 'Hexal' name?

A: Enac Hexal contains the active ingredient enalapril maleate. From a pharmacological standpoint, this active ingredient is chemically and therapeutically the same as the enalapril found in other generic and brand-name formulations, regardless of the manufacturer name 'Hexal'.

Q: Can Enac Hexal cause problems with electrolyte balance?

A: Yes, official safety data lists hyperkalemia (abnormally high levels of potassium in the blood) as a common adverse reaction. Since potassium is an important electrolyte, this indicates that the medicine has the potential to affect the body's electrolyte balance, often requiring monitoring.

Q: Are there any known issues with taking Enac Hexal and aspirin together?

A: Regulatory documents state that taking Enac Hexal with high-dose aspirin for pain relief should be done cautiously, as it can increase the risk of worsening kidney function. However, the use of low-dose aspirin (e.g., for cardiovascular protection) is generally considered safe.

How should Enac Hexal be stored and disposed of?

How to Store and Dispose of Enac Hexal

This section outlines the official regulatory requirements for storing, handling, and disposing of Enac Hexal (Enalapril Maleate) to maintain its stability.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection Keep in the original container, tightly closed, and protect from moisture and light.
Prohibitions Do not freeze or expose to excessive heat. Do not store above 25 C for some packaging.
Stability Keep out of the reach of children. Oral solutions must be discarded after 60 days of storage at room temperature.

Disposal Instructions

Unused or expired Enac Hexal must be disposed of according to local and national pharmaceutical waste regulations. Regulatory documents advise against disposal via household trash or flushing down a sink or toilet to minimize environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enac Hexal found in:

A-Z Index: